The authors’ approach is deceptively simple: take an aldehyde dehydrogenase enzyme, which naturally converts aldehydes to acids, and get it to react with an amine instead of water. But actually making ...

Researchers at the University of São Paulo (USP) in Brazil, partnering with Foresee Pharmaceuticals, a Taiwan and US-based biopharmaceutical company, have tested a synthetic molecule for the treatment ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

KAYO-1732 is a novel, orally available, small-molecule inhibitor of the aldehyde dehydrogenase 1A3 (ALDH1A3) enzyme, being developed for the treatment of type 2 diabetes and cardiovascular disorders.